Mohammed Ansari, MD
Nephrology · Chicago, ILNPI 1487688131
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $23,111 of the $25,362 with a category attached, or 91.1%. 5 manufacturers reported payments, led by Vertex at 45.0% of the total. Among nephrology clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 25 payments — averaging $1014.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vertex$11K
- Apellis Pharmaceuticals, Inc.$7K
- Mallinckrodt Enterprises LLC$7K
- Novartis$46
- Covidien LP$21
What the payments were for
- Consulting fees$23,11191%
- Travel & lodging$1,9818%
- Food & beverage$2711%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vertex | 14 | $11,423 |
| Apellis Pharmaceuticals, Inc. | 6 | $7,314 |
| Mallinckrodt Enterprises LLC | 2 | $6,559 |
| Novartis | 2 | $46 |
| Covidien LP | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UVADEX$6,500
How this compares
$25,362 in reported general payments places this provider in the 90th percentile of 524 nephrology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cinacalcet Hcl | 74 | $29,772 |
| Tacrolimus | 63 | $10,479 |
| Atovaquone | 13 | $9,205 |
| Mycophenolate Mofetil | 56 | $8,205 |
| RetacritEpoetin Alfa-Epbx | 12 | $8,181 |
| EliquisApixaban | 12 | $7,805 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 456 | $2,530 |
| Nifedipine ErNifedipine | 67 | $1,824 |
| Mycophenolic AcidMycophenolate Sodium | 11 | $1,143 |
| Losartan Potassium | 79 | $1,083 |
| Carvedilol | 119 | $1,065 |
| Leflunomide | 18 | $942 |
| Prednisone | 98 | $893 |
| Valganciclovir Hcl | 11 | $761 |
| Bumetanide | 21 | $743 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Chicago
- Myles WolfChicago$2.1M
- Susan QuagginChicago$262K
- Nicole StankusChicago$235K
- Marco BonillaChicago$148K
- Lorenzo GallonChicago$120K
- Vikram AggarwalChicago$117K
- Jay KoynerChicago$113K
- Jose ArrudaChicago$107K
- John FriedewaldChicago$93K
- Casey GashtiChicago$74K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.